Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
The Sprouting Company is a science-led consumer health company dedicated to making the health benefits of sulforaphane accessible through high-potency broccoli sprout products. Co-founded by Dr. Jed Fahey, a pioneer in nutritional biochemistry from Johns Hopkins University, the company utilizes proprietary sprouting techniques to ensure maximum bioavailability of glucoraphanin and myrosinase. Their product line includes specialized sprouting kits and supplements designed to activate the Nrf2 pathway, which plays a critical role in cellular defense and detoxification. By bridging the gap between rigorous clinical research and daily nutrition, The Sprouting Company positions itself at the intersection of functional food and preventative health. The company's mission is to provide a reliable, standardized source of one of nature's most potent health-promoting molecules for the longevity and wellness markets.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on The Sprouting Company.